Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SKB571 in gastrointestinal tumors
CTR20261464Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SKB571 in gastrointestinal cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 2 more, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Primary endpoint: Objective response rate. Started May 2026; status: active.
02
Drugs
SKB571
03
Conditions
gastrointestinal cancergastric adenocarcinomagastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20261464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261464.